SIGA vs. SLN, ORIC, ZYME, LYEL, LBPH, NUVB, AVTE, BCYC, ATXS, and YMAB
Should you be buying SIGA Technologies stock or one of its competitors? The main competitors of SIGA Technologies include Silence Therapeutics (SLN), ORIC Pharmaceuticals (ORIC), Zymeworks (ZYME), Lyell Immunopharma (LYEL), Longboard Pharmaceuticals (LBPH), Nuvation Bio (NUVB), Aerovate Therapeutics (AVTE), Bicycle Therapeutics (BCYC), Astria Therapeutics (ATXS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Silence Therapeutics (NASDAQ:SLN) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 2.2% of SIGA Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Silence Therapeutics received 16 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 70.00% of users gave Silence Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote.
In the previous week, SIGA Technologies had 5 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for SIGA Technologies and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.39 beat SIGA Technologies' score of -0.05 indicating that SIGA Technologies is being referred to more favorably in the news media.
SIGA Technologies has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.
Silence Therapeutics currently has a consensus price target of $57.25, indicating a potential upside of 164.80%. Given SIGA Technologies' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than SIGA Technologies.
Silence Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
SIGA Technologies has a net margin of 48.65% compared to SIGA Technologies' net margin of -171.41%. Silence Therapeutics' return on equity of 44.84% beat SIGA Technologies' return on equity.
Summary
SIGA Technologies beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.
Get SIGA Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SIGA Technologies Competitors List
Related Companies and Tools
